nSPire Group CGuard EPS Carotid Stent Platform Investor Presentation

nSPire Group presents its CGuard EPS carotid stent platform utilizing proprietary MicroNet technology for treatment of carotid artery disease and stroke prevention. The company highlights unmatched clinical outcomes from ten completed trials with over 2,000 patients, expanding commercial footprint with market share in 30+ countries, and FDA approval anticipated in H1 2025 for CGuard Prime EPS.